A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open label, randomized, allopurinol-controlled, parallel-design study.
Approximately 120 subjects will be randomly assigned in 1:1 ratio to receive febuxostat, or
allopurinol for subjects with gout.